News articles about ARCA biopharma (NASDAQ:ABIO) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ARCA biopharma earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.8302136391894 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
ARCA biopharma (NASDAQ:ABIO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.59) EPS for the quarter.
TRADEMARK VIOLATION NOTICE: “ARCA biopharma (ABIO) Receives Coverage Optimism Score of 0.05” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.com-unik.info/2017/11/01/arca-biopharma-abio-receives-coverage-optimism-score-of-0-05.html.
ARCA biopharma Company Profile
ARCA biopharma, Inc (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF).
What are top analysts saying about ARCA biopharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ARCA biopharma Inc. and related companies.